When cell and gene therapies were coming as one at a time, initially for rare diseases, the impact on payers could be minimized. But now that a big wave of regenerative medicines for a wider array of diseases is hitting the commercial market, they could have a significant impact on the bottom line, companies acknowledged during the Alliance for Regenerative Medicine's (ARM's) recent Cell and Gene Meeting on the Mesa.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?